

# DPC 817



**Brand Name:** Reverset

**Drug Class:** Nucleoside Reverse Transcriptase Inhibitors

DPC 817, also known as dexelvucitabine, DFC, or Reverset, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs work by blocking reverse transcriptase, a protein that HIV needs to make more copies of itself.

## HIV/AIDS-Related Uses

DPC 817 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It was being studied for the treatment of HIV infection. All trials were stopped in early 2006, because severe side effects occurred in nearly half of the evaluated patients. There are no plans to renew study at this time.

This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

## Dosage Form/Administration

DPC 817 comes in enteric-coated tablet and buffered oral solution forms and is taken by mouth.

## Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

## Possible Side Effects

Along with its desired effects, DPC 817 may cause some unwanted effects. Further study is needed to determine the possible side effects of DPC 817. Individuals should tell a doctor if they experience side effects that are bothersome.

A Phase II study showed that 40% of patients taking DPC 817 alone experienced high lipase levels. High levels of lipase sometimes result from a serious condition called pancreatitis, or inflammation of the pancreas. Patients taking DPC 817 in a clinical trial should contact investigators at the study site to discuss other treatment options.

## Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

## Clinical Trials

For information on clinical trials that involve DPC 817, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box, enter: DPC 817 AND HIV Infections.

## Manufacturer Information

DPC 817  
Incyte Corporation  
Experimental Station  
Route 141 & Henry Clay Road  
Building E336  
Wilmington, DE 19880  
(302) 498-6700

Reverset  
Pharmasset, Inc.  
US Research Operations  
1860 Montreal Road  
Tucker, GA 30084  
(678) 395-0035

## For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: [http://aidsinfo.nih.gov/live\\_help](http://aidsinfo.nih.gov/live_help) Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET